{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:19:14Z","timestamp":1790965154979,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejim.2025.106554","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:56:13Z","timestamp":1760799373000},"page":"106554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Crystal clear \u2013 Part II: the role of uric acid in cardiorenal disease"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo FG","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2890","key":"10.1016\/j.ejim.2025.106554_bib0001","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(02)46030-8","article-title":"On chronic bright\u2019s disease, and its essential symptoms","volume":"113","author":"Mahomed","year":"1879","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0002","first-page":"288","article-title":"On uric acid and arterial tension","volume":"1889","author":"Haig","year":"1467","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0003","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.106554_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijcard.2015.08.086","article-title":"Uric acid and coronary artery disease: an elusive link deserving further attention","volume":"213","author":"Biscaglia","year":"2016","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0005","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0006","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","article-title":"Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction","volume":"28","author":"Yu","year":"2010","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.ejim.2025.106554_bib0007","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","article-title":"Uric Acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk","author":"Borghi","year":"2022","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ejim.2025.106554_bib0008","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1291\/hypres.27.835","article-title":"Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan","volume":"27","author":"Nagahama","year":"2004","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/01.HYP.0000248752.08807.4c","article-title":"Uric acid and the development of hypertension: the normative aging study","volume":"48","author":"Perlstein","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.106554_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1047-2797(99)00037-X","article-title":"Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) study","volume":"10","author":"Moriarity","year":"2000","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ejim.2025.106554_bib0011","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.183244","article-title":"Uric acid level and elevated blood pressure in US adolescents: national health and nutrition examination survey, 1999-2006","volume":"59","author":"Loeffler","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.106554_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006683","article-title":"Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study","volume":"6","author":"Gunawardhana","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2025.106554_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00701.x","article-title":"Effect of allopurinol on blood pressure: a systematic review and meta-analysis","volume":"15","author":"Agarwal","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2025.106554_bib0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jch.14153","article-title":"Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia","volume":"23","author":"Kario","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ejim.2025.106554_bib0015","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.41749","article-title":"Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial","volume":"73","author":"Gaffo","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.ejim.2025.106554_bib0017","article-title":"Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2025.106554_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/HJH.0000000000002316","article-title":"Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort","volume":"38","author":"Jiang","year":"2020","journal-title":"J. Hypertens."},{"issue":"15","key":"10.1016\/j.ejim.2025.106554_bib0019","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jacc.2022.02.010","article-title":"Sex differences in cardiovascular consequences of hypertension, obesity, and diabetes: JACC Focus Seminar 4\/7","volume":"79","author":"Regensteiner","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0020","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41440-023-01535-0","article-title":"Sex-specific associations between serum uric acid levels and risk of hypertension for different diagnostic reference values of high blood pressure","volume":"47","author":"Salim","year":"2024","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.ejim.2025.106554_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.numecd.2023.10.027","article-title":"Associations of serum uric acid with hypertension status, stages, phenotypes and progressions among Chinese middle-aged and elderly","volume":"34","author":"Li","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/HJH.0000000000003597","article-title":"Association of serum uric acid levels with blood pressure and the incidence of hypertension in the middle-aged and elderly populations","volume":"42","author":"Sasaki","year":"2024","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0023","article-title":"Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions","volume":"14","author":"Freilich","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.ejim.2025.106554_bib0024","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41440-020-0481-6","article-title":"Uric acid and hypertension","volume":"43","author":"Lanaspa","year":"2020","journal-title":"Hypertens Res"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0025","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41440-023-01273-3","article-title":"Update in uric acid, hypertension, and cardiovascular diseases","volume":"46","author":"Kuwabara","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2025.106554_bib0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejim.2016.07.026","article-title":"High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects","volume":"37","author":"Cicero","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0027","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12916-025-04195-8","article-title":"Physiological serum uric acid concentrations correlate with arterial stiffness in a sex-dependent manner","volume":"23","author":"Thews","year":"2025","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0028","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1742-1241.2009.02263.x","article-title":"The association between serum uric acid level and coronary artery disease","volume":"64","author":"Sinan Deveci","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0029","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0030","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","article-title":"Serum uric acid and coronary heart disease in 9458 incident cases and 155,084 controls: prospective study and meta-analysis","volume":"2","author":"Wheeler","year":"2005","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.reuma.2019.08.003","article-title":"Asymptomatic hyperuricaemia and coronary artery disease","volume":"17","author":"Miranda-Aquino","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0032","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/HJH.0000000000003319","article-title":"Serum uric acid \/serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values","volume":"41","author":"Casiglia","year":"2023","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/cclm-2015-0523","article-title":"Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis","volume":"54","author":"Braga","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"13","key":"10.1016\/j.ejim.2025.106554_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020180","article-title":"Cumulative serum uric acid and its time course are associated with risk of myocardial infarction and all-cause mortality","volume":"10","author":"Tian","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.ejim.2025.106554_bib0035","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.amjcard.2015.07.059","article-title":"Relation of lipid content of coronary plaque to level of serum uric acid","volume":"116","author":"Saito","year":"2015","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0036","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0003319713500706","article-title":"Association between uric acid and coronary collateral circulation in patients with stable coronary artery disease","volume":"65","author":"Uysal","year":"2014","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0037","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/eci.12039","article-title":"Uric acid and prognosis in angiography-proven coronary artery disease","volume":"43","author":"Ndrepepa","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2025.106554_bib0038","article-title":"The U-shaped relationship between serum uric acid and long-term all-cause mortality in coronary artery disease patients: a cohort study of 33,034 patients","volume":"9","author":"Zheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2025.106554_bib0039","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.025","article-title":"Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention","volume":"297","author":"Lim","year":"2020","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.ejim.2025.106554_bib0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10067-015-2878-1","article-title":"Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease","volume":"34","author":"Dai","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0041","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.numecd.2021.03.007","article-title":"Genetically predicted serum uric acid levels and the risk of coronary artery disease in patients with diabetes: a mendelian randomization study","volume":"31","author":"Chen","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2025.106554_bib0042","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2018.09.107","article-title":"Canizales-Quinteros S. Genetic contributors to serum uric acid levels in Mexicans and their effect on premature coronary artery disease","volume":"279","author":"Macias-Kauffer","year":"2019","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.ejim.2025.106554_bib0043","article-title":"Association between serum uric acid levels and oxido-inflammatory biomarkers with coronary artery disease in type 2 diabetic patients","volume":"15","author":"Gharib","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0044","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.numecd.2021.01.023","article-title":"Uric acid in chronic coronary syndromes: relationship with coronary artery disease severity and left ventricular diastolic parameter","volume":"31","author":"Maloberti","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12882-021-02463-2","article-title":"Serum uric acid is associated with coronary artery calcification in early chronic kidney disease: a cross-sectional study","volume":"22","author":"Han","year":"2021","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0046","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/HJH.0000000000002287","article-title":"Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the URRAH (Uric Acid Right for Heart Health) study","volume":"38","author":"Casiglia","year":"2020","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.ejim.2025.106554_bib0047","doi-asserted-by":"crossref","first-page":"675","DOI":"10.6026\/97320630018675","article-title":"Correlation of inflammatory cytokines and uric acid levels in coronary artery disease with and without type 2 diabetes mellitus","volume":"18","author":"Selvakumar","year":"2022","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejim.2025.106554_bib0048","doi-asserted-by":"crossref","unstructured":"Liu W., Ding K., Bao J., Hu Y., Gui Y., Ye L., Wang L. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting. Coron Artery dis. 2023;34(8):589\u2013594. doi: 10.1097\/MCA.0000000000001300.","DOI":"10.1097\/MCA.0000000000001300"},{"issue":"10","key":"10.1016\/j.ejim.2025.106554_bib0049","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41440-023-01331-w","article-title":"Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease","volume":"46","author":"Shimizu","year":"2023","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40292-018-0250-7","article-title":"Working Group on Uric Acid and cardiovascular risk of the Italian Society of Hypertension. Exploration into Uric and cardiovascular disease: uric Acid right for heArt Health (URRAH) Project, A study protocol for a retrospective observational study","volume":"25","author":"Desideri","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"15","key":"10.1016\/j.ejim.2025.106554_bib0051","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1111\/jcmm.15523","article-title":"Soluble uric acid induces myocardial damage through activating the NLRP3 inflammasome","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"11","key":"10.1016\/j.ejim.2025.106554_bib0052","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0053","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/metabo15070424","article-title":"Uric acid, colchicine and chronic inflammatory diseases: a cardiovascular perspective","volume":"15","author":"Alunno","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.ejim.2025.106554_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120448","article-title":"Colchicine in the secondary prevention of stroke and major cardiovascular events in patients with stroke or at high risk of it: systematic review and meta-analysis","volume":"408","author":"Hagag","year":"2025","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.ejim.2025.106554_bib0055","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1111\/jcmm.16798","article-title":"Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.106554_bib0056","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","article-title":"Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0057","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0058","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10741-019-09869-z","article-title":"Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure","volume":"25","author":"Borghi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2025.106554_bib0059","article-title":"Abu Rmilah A. Hyperuricemia and cardiovascular risk: insights and implications","author":"Shubietah","year":"2025","journal-title":"Crit Pathw Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0060","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1067\/mhj.2001.114367","article-title":"Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance","volume":"141","author":"Doehner","year":"2001","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0061","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12872-025-04481-6","article-title":"Gender differences in the prognostic impact of uric acid in patients with heart failure and preserved ejection fraction","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2025.106554_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.106554_bib0063","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2015.08.089","article-title":"Uric acid and xanthine oxidase in heart failure - emerging data and therapeutic implications","volume":"213","author":"Doehner","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306353","article-title":"Association between mixed venous oxygen saturation and serum uric acid levels in patients with heart failure","volume":"20","author":"Mashitani","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12872-025-04675-y","article-title":"The role of cut-off values for creatinine, blood urea nitrogen, and uric acid in prognostic assessment of chronic heart failure: a retrospective cohort study","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2025.106554_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.033","article-title":"Prognostic impact of uric acid levels in heart failure with mildly reduced ejection fraction: insights from a large retrospective registry","author":"Schmitt","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0067","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/jcm14061934","article-title":"Prognostic markers of adverse outcomes in acute heart failure: use of machine learning and network analysis with real clinical data","volume":"14","author":"Shchekochikhin","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0068","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/HJH.0000000000002589","article-title":"from the Working Group on Uric Acid, Cardiovascular Risk of the Italian Society of Hypertension. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid right for heArt Health study","volume":"39","author":"Muiesan","year":"2021","journal-title":"J Hypertens"},{"issue":"13","key":"10.1016\/j.ejim.2025.106554_bib0069","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejim.2025.106554_bib0070","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/14656566.2018.1532503","article-title":"The future of febuxostat after the Cardiovascular Safety ofuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?","volume":"19","author":"Katsiki","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2025.106554_bib0071","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol or no urate-lowering treatment in people with gout: a cohort study in UK primary care using the Clinical Practice Research Datalink","volume":"64","author":"Partington","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-099442","article-title":"Effects of febuxostat on heart failure patients with asymptomatic hyperuricaemia: a retrospective cohort study","volume":"15","author":"Long","year":"2025","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.ejim.2025.106554_bib0073","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"21","key":"10.1016\/j.ejim.2025.106554_bib0074","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejim.2025.106554_bib0075","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.12998\/wjcc.v12.i18.3468","article-title":"Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia","volume":"12","author":"Lin","year":"2024","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0076","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12933-024-02214-1","article-title":"Gender differences in the relationship between serum uric acid and the long-term prognosis in heart failure: a nationwide study","volume":"23","author":"Fu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0077","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13019-024-03209-5","article-title":"Risk of myocardial infarction and heart failure in gout patients: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2025","journal-title":"J Cardiothorac Surg"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0078","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s40001-025-02403-y","article-title":"A retrospective study of the association between serum uric acid and risk of coronary heart disease complicated with different types of chronic heart failure","volume":"30","author":"Yu","year":"2025","journal-title":"Eur J Med Res"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0079","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.11.051","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies","volume":"232","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ejim.2025.106554_bib0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41371-021-00613-5","article-title":"Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study","volume":"36","author":"Tikhonoff","year":"2022","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ejim.2025.106554_bib0081","doi-asserted-by":"crossref","unstructured":"Deng X., Kuang K., Zhong Y., Lai R., Lv X., Liu S., Liu M., Liang J., Yang D. The association between kidney function-standardized serum uric acid levels and stroke risk: insights from the National Health and Nutrition Examination Survey. Front Aging Neurosci. 2025;17:1542298. doi: 10.3389\/fnagi.2025.1542298.","DOI":"10.3389\/fnagi.2025.1542298"},{"key":"10.1016\/j.ejim.2025.106554_bib0082","article-title":"Serum uric acid\/creatinine ratio and 1-year stroke recurrence in patient with acute ischemic stroke and abnormal renal function: results from the Xi'an stroke registry study of China","volume":"16","author":"Liu","year":"2025","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106554_bib0083","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jch.12855","article-title":"Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta-analysis","volume":"18","author":"Qin","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1016\/j.ejim.2025.106554_bib0084","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/STROKEAHA.124.048748","article-title":"Leira EC; SPAN investigators. Uric acid stroke cerebroprotection transcended sex, age, and comorbidities in a multicenter preclinical trial","volume":"56","author":"Patel","year":"2025","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0085","first-page":"S28","article-title":"Uric acid levels are relevant in patients with stroke treated with thrombolysis","volume":"42","author":"Amaro","year":"2011","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.ejim.2025.106554_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.103909","article-title":"Association between serum uric acid to high-density lipoprotein cholesterol ratio and all-cause and cardiovascular disease mortality after stroke: a cross-sectional study from 2005 to 2018","volume":"35","author":"Ding","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2025.106554_bib0087","doi-asserted-by":"crossref","DOI":"10.1093\/arclin\/acaf021","article-title":"Development and validation of a risk prediction model for depression in patients with stroke","author":"Lin","year":"2025","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0088","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/23969873231209620","article-title":"Serum uric acid and prognosis of ischemic stroke: cohort study, meta-analysis and mendelian randomization study","volume":"9","author":"Zhong","year":"2024","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.ejim.2025.106554_bib0089","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/NDT.S373493","article-title":"Uric acid and clinical outcomes in young patients with ischemic stroke","volume":"18","author":"Liu","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/ijms23020602","article-title":"Potential biomarkers for post-stroke cognitive impairment: a systematic review and meta-analysis","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0091","first-page":"190","article-title":"A randomized controlled trial of allopurinol in patients with peripheral arterial disease","volume":"32","author":"Robertson","year":"2016","journal-title":"Can J Cardiol"},{"issue":"23","key":"10.1016\/j.ejim.2025.106554_bib0092","first-page":"11472","article-title":"Relationship between uric acid albumin ratio and peripheral artery disease complexity","volume":"27","author":"Oflar","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejim.2025.106554_bib0093","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.avsg.2024.05.032","article-title":"The effect of uric acid and albumin ratio in undergoing lower extremity endovascular interventions for peripheral arterial disease related contrast induced nephropathy","volume":"108","author":"Demirci","year":"2024","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ejim.2025.106554_bib0094","doi-asserted-by":"crossref","first-page":"1197628","DOI":"10.3389\/fendo.2023.1197628","article-title":"Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension","volume":"14","author":"Han","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejim.2025.106554_bib0095","doi-asserted-by":"crossref","first-page":"1405301","DOI":"10.3389\/fendo.2024.1405301","article-title":"Incidence and risk factors for amputation in Chinese patients with diabetic foot ulcers: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"10.1016\/j.ejim.2025.106554_bib0096","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/diagnostics13193145","article-title":"Gender differences and amputation risk in peripheral artery disease-A single-center experience","volume":"13","author":"Onofrei","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0097","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42347","article-title":"Comparison of rates of lower extremity amputation in patients with and without gout in the US Department of Veterans Affairs Health system","volume":"5","author":"Mikuls","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"No. 6","key":"10.1016\/j.ejim.2025.106554_bib0098","first-page":"879","volume":"72","author":"FitzGerald","year":"2020","journal-title":"American College of Rheumatology Guideline for the Management of Gout: Arthritis & Rheumatology"},{"key":"10.1016\/j.ejim.2025.106554_bib0099","first-page":"1","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"0","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HJH.0000000000002721","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.ejim.2025.106554_bib0101","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0102","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.ejim.2025.106554_bib0103","doi-asserted-by":"crossref","unstructured":"Cicero A.F.G., Fogacci F., Kuwabara M., Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: an evidence-based update. Medicina (Kaunas). 2021;57(1):58. doi: 10.3390\/medicina57010058.","DOI":"10.3390\/medicina57010058"},{"issue":"12","key":"10.1016\/j.ejim.2025.106554_bib0104","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/j.numecd.2021.09.011","article-title":"Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs","volume":"31","author":"Fogacci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.14570","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"24","author":"Hu","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0106","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0107","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"You","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.ejim.2025.106554_bib0108","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ejim.2025.106554_bib0109","article-title":"Pharmacotherapy for hyperuricaemia in hypertensive patients","volume":"9","author":"Gois","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/HYPERTENSIONAHA.120.16547","article-title":"Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials","volume":"77","author":"Gill","year":"2021","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejim.2025.106554_bib0111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0003319719897509","article-title":"Effect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies","volume":"71","author":"Kanbay","year":"2020","journal-title":"Angiology"},{"issue":"8","key":"10.1016\/j.ejim.2025.106554_bib0112","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.3390\/ijms24087027","article-title":"Purine metabolism dysfunctions: experimental methods of detection and diagnostic potential","volume":"24","author":"Cicero","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.106554_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1190069","article-title":"Gout and hyperuricaemia: modifiable cardiovascular risk factors?","volume":"10","author":"Burnier","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0114","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41401-025-01476-z","article-title":"Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies","volume":"46","author":"Zhao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/0115734021277772240124075120","article-title":"Xanthine oxidoreductase in the pathogenesis of endothelial dysfunction: an update","volume":"20","author":"Mudgal","year":"2024","journal-title":"Curr Hypertens Rev"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0116","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric Acid and cardiovascular Disease: an update","volume":"11","author":"Muiesan","year":"2016","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.ejim.2025.106554_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102271","article-title":"U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia","volume":"51","author":"Crawley","year":"2022","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0118","first-page":"3","article-title":"Sleep apnea as a cause of gout flares","volume":"11","author":"Abrams","year":"2009","journal-title":"Medscape J Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.106554_bib0119","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/HJH.0000000000002026","article-title":"2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH\/ESC Task Force for the Management of arterial Hypertension: erratum","volume":"37","year":"2019","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0120","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension."},{"issue":"12","key":"10.1016\/j.ejim.2025.106554_bib0121","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2025.106554_bib0122","first-page":"603","article-title":"Chinese hypertension guidelines revision committee. 2024 Chinese guidelines for prevention and treatment of hypertension","volume":"33","year":"2024","journal-title":"Chin J Hypertens"},{"key":"10.1016\/j.ejim.2025.106554_bib0123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"38","key":"10.1016\/j.ejim.2025.106554_bib0124","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HJH.0000000000003899","article-title":"LASH Guidelines Task Force Steering and Writing Committee. 2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America","volume":"43","author":"S\u00e1nchez","year":"2025","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2025.106554_bib0126","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejim.2025.106554_bib0127","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmed.2018.00160","article-title":"Physiology of hyperuricemia and urate-lowering treatments","volume":"5","author":"Benn","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejim.2025.106554_bib0128","doi-asserted-by":"crossref","DOI":"10.1177\/11795468241239542","article-title":"Impact of hyperuricemia and urate-lowering agents on cardiovascular diseases","volume":"18","author":"Sosa","year":"2024","journal-title":"Clin Med Insights Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106554_bib0129","doi-asserted-by":"crossref","first-page":"320","DOI":"10.14740\/jocmr6250","article-title":"The long-term effects of the selective inhibitor of Urate transporter 1, Dotinurad, on metabolic parameters and renal function in Japanese patients with asymptomatic hyperuricemia","volume":"17","author":"Yanai","year":"2025","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.ejim.2025.106554_bib0130","first-page":"106","article-title":"Premature mortality with gout and hyperuricemia may be reduced by early resolution of comorbid obstructive sleep apnea","volume":"1","author":"Burton","year":"2023","journal-title":"Explor Musculoskeletal Dis"},{"issue":"4","key":"10.1016\/j.ejim.2025.106554_bib0131","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/art.42731","article-title":"Determinants of achieving serum urate goal with treat-to-target urate-lowering therapy in gout","volume":"76","author":"Helget","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525004315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525004315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:16:32Z","timestamp":1764659792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525004315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":131,"alternative-id":["S0953620525004315"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106554","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crystal clear \u2013 Part II: the role of uric acid in cardiorenal disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106554"}}